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OBJECTIVE—In the Canadian Normoglycemia Outcome Evaluation (CANOE) trial, low-
dose rosiglitazone/metformin reduced the risk of diabetes in subjects with impaired glucose
tolerance by 66% over a median of 3.9 years. We evaluate the temporal changes in glycemic
control, insulin sensitivity, and b-cell function during this trial.
RESEARCH DESIGN AND METHODS—CANOE participants (n = 207) underwent
annual oral glucose tolerance testing, enabling temporal comparison of glycemia, insulin sensi-
tivity (Matsuda index), and b-cell function (insulin secretion-sensitivity index-2 [ISSI-2]) be-
tween the rosiglitazone/metformin and placebo arms.
RESULTS—Glycemic parameters and insulin sensitivity improved in the rosiglitazone/
metformin arm inyear1,but deteriorated inthe years thereafterasinthe placeboarm. Generalized
estimating equation analysis conﬁrmed that both insulin sensitivity and b-cell function decreased
over time (Matsuda: b = 20.0515, P , 0.0001; ISSI-2: b = 26.6507, P , 0.0001), with no
signiﬁcant time-by-treatment interaction (Matsuda: P = 0.57; ISSI-2: P =0 . 2 2 ) .
CONCLUSIONS—Despite preventing incident diabetes, low-dose rosiglitazone/metformin
did not modify the natural history of worsening insulin resistance and b-cell dysfunction.
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A
lthough lifestyle modiﬁcation and
antidiabetic medications can pre-
vent the development of type 2
diabetes (T2D) in patients with impaired
glucose tolerance (IGT) (1–7), the long-
term durability of these interventions
will likely depend on their capacity to
modify the insulin resistance and b-cell
dysfunction that is characteristic of T2D
(8). The recently reported Canadian
Normoglycemia Outcome Evaluation
(CANOE) trial was a double-blind,
placebo-controlled trial in which low-
dose rosiglitazone/metformin therapy
was shown to reduce the risk of incident
T2D in subjects with IGT by 66% over a
medianof3.9years(9).Forinsightonthe
disease-modifying capacity of this inter-
vention, we conducted the current analy-
sis to compare the temporal changes over
time in glycemic control, insulin sensitiv-
ity,andb-cellfunction between thestudy
arms during this trial.
RESEARCH DESIGN AND
METHODS—Detailed descriptions of
the CANOE protocol (www.clinicaltrial.
gov: NCT00116922) have been reported
(9,10). Brieﬂy, 207 subjects with IGT were
randomly assigned to either rosiglitazone/
metformin 2/500 mg b.i.d. or identical
placebo. All participants received a life-
style intervention. The study was ap-
proved by the institutional research
ethics boards, and all subjects provided
w r i t t e ni n f o r m e dc o n s e n t .
During the trial, participants under-
went an annual 2-h, 75-g oral glucose
tolerance test (OGTT), with sampling at
0,30,and120min.Insulinsensitivitywas
evaluated with the Matsuda index, and
b-cell function was assessed using the
insulin secretion-sensitivity index-2
(ISSI-2), an OGTT-derived measure anal-
ogous to the disposition index obtained
from the intravenous glucose tolerance
test (11,12). The Matsuda index and
ISSI-2 were calculated from the same
OGTT, with formulae as previously de-
scribed (9,11,12).
All analyses were conducted using
SAS 9.2 (SAS Institute, Inc., Cary, NC).
The patterns of change over time in glyce-
micmeasures,insulinsensitivity,andb-cell
function are evaluated in Fig. 1. For each
measure,generalizedestimatingequation
(GEE) modelswerethen constructedtoas-
sessfor1)atreatmenteffectofrosiglitazone/
metformin versus placebo, 2) an effect
of time on each response, and 3)at i m e -
by-treatment interaction (indicating a sig-
niﬁcant difference between the treatment
groups in the rate of change in response
over time).
RESULTS—Detailed baseline and out-
comeresultsforthetrialhavebeenreported
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Pathophysiology/Complications
BRIEF REPORT(9). At baseline, there were no signiﬁcant
differences between the placebo (n =1 0 4 )
androsiglitazone/metformin(n=103)arms
in age, sex, ethnicity, anthropometry, in-
sulin sensitivity,b-cell function, and glu-
cose homeostasis(SupplementaryTable1).
A ss h o w ni nF i g .1 A–D, all glycemic
measures (fasting, 30-min, and 2-h glu-
cose, and area under the glucose curve
[AUCgluc]) decreased in the ﬁrst year in
the rosiglitazone/metformin arm, whereas
only 2-h glucose and AUCgluc declined
over this time in the placebo arm (albeit
toalesserdegree).Thereafter,from12–60
months, however, both arms showed a
strikingly similar proﬁle of increasing gly-
cemiawithallfourmeasures.Furthermore,
this pattern of improvement in year 1 fol-
lowed by subsequent worsening in the
years thereafter mirrored that observed
for insulin sensitivity, becausethe Matsuda
index initially increased to a greater extent
in the active treatment arm than in the pla-
cebo group, before declining similarly in
both groups over time (Fig. 1E). In con-
trast, both groups exhibited relative stabil-
ity of b-cell function (ISSI-2) for the ﬁrst 2
years, followed by progressive deteriora-
tion in the subsequent years (Fig. 1F). As
previously reported, both study arms
Figure 1—Changes in mean levels of fasting glucose (A), 30-min glucose (B), 2-h glucose (C), AUCgluc (D), Matsuda index (E), and ISSI-2 (F)i n
the rosiglitazone/metformin and placebo arms over 60 months.
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Metformin/TZD therapy in IGTshowed similar patterns of change in BMI
andwaistcircumferenceduringthetrial(9).
GEE analyses revealed that each gly-
cemic measure was increasing over time
in the study population (fasting glucose:
b = 0.0063, P , 0.0001; 30-min glucose:
b = 0.0126, P = 0.0004; 2-h glucose: b =
0.0115, P = 0.0116; AUCgluc: b = 0.0231,
P = 0.0002). In each case, there was a sig-
niﬁcant treatment effect, such that the
glycemic measure was lower in the rosi-
glitazone/metformin arm during the trial
(fasting glucose: b = 20.3234, P ,
0.0001; 30-min glucose: b = 20.9025,
P , 0.0001; 2-h glucose: b = 20.6402,
P = 0.0091; AUCgluc: b = 21.4141, P ,
0.0001). There were no signiﬁcant time-
by-treatment interactions (data not shown).
Insulin sensitivity and b-cell function
also decreased signiﬁcantly over time in
both groups (Matsuda: b = 20.0515,
P , 0.0001; ISSI-2: b = 26.6507, P ,
0.0001). Again, a treatment effect was ap-
parent because both measures were
higher in the rosiglitazone/metformin
arm during the trial (Matsuda: b =
1.8805, P , 0.0001; ISSI-2: b = 79.1788,
P , 0.0001), but there was no signiﬁcant
time-by-treatment interaction (Matsuda:
P = 0.57; ISSI-2: P = 0.22), indicating no
differences between the groups in the rate
of change over time.
CONCLUSIONS—Thisanalysisshows
that the glycemic improvement in the
rosiglitazone/metformin arm in year 1
was not sustained, with all glycemic pa-
rameters worsening thereafter at a similar
rate in both arms (Fig. 1A–D). It thus
seems that the marked risk reduction for
T2D was driven by the glucose-lowering
effect of rosiglitazone/metformin in the
ﬁrst year. Indeed, this effect was of suf-
ﬁcient magnitude that it took 4 years for
the 2-hour glucose level in the treatment
arm to increase to the level seen in the pla-
cebo arm at the end of year 1. Overall, this
pattern is suggestive of a delay in the de-
velopment of T2D rather than a disease-
modifying preventive effect, consistent
with the ﬁndings of the Diabetes Reduc-
tion Assessment with Ramipril and Rosi-
glitazone Medication Ongoing Follow-up
(DREAM On) study, which similarly sug-
gested that full-dose rosiglitazone delayed
diabetes rather than prevented it (13).
Thecurrentanalysisfurtheraddresses
the question of disease modiﬁcation by
considering the changes over time in in-
sulin sensitivity and b-cell function during
thetrial.Thesechanges(Fig.1E–F)sugg est
that the initial glycemic improvement in
the rosiglitazone/metformin arm was
likely due to enhanced insulin sensitivity
in year 1, rather than improved b-cell
function.Afteryear1,though,insulinsen-
sitivity declined at a similar rate in both
arms. This waning insulin sensitization af-
ter the ﬁrst year is similar to that which
w a so b s e r v e dw i t hb o t hm e t f o r m i na n d
lifestyle in the Diabetes Prevention Pro-
gram (14). Most tellingly, the current
GEE analyses conﬁrmed that both insulin
sensitivity and b-cell function declined
during the CANOE trial, with no differ-
ence between the study arms in the rate
of change over time for either measure.
Taken together, these data suggest that
low-doserosiglitazone/metformintherapy
had an early effect that decreased the sub-
sequent development of diabetes during
the trial but did not modify the natural
history of worsening insulin resistance
and b-cell dysfunction over time. As
such, at the low doses from this trial, this
combination therapy does not seem to
have a long-term disease-modifying effect
on the development of T2D in patients
with IGT.
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